

B-1
cont
having the effect of activating Rho is oleoyl lysophosphatidic acid.

4. (Amended) The therapeutic agent composition for the corneal disorder as claimed in claim 1, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

M
5. (Amended) A corneal epithelial migration promoter composition comprising a compound having an effect of activating Rho as an active ingredient and a pharmacological carrier.

Please add the following new claims 6-13:

Sub
B-2
6. (New) The therapeutic agent composition for the corneal disorder as claimed in claim 2, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

AS
7. (New) The therapeutic agent composition for the corneal disorder as claimed in claim 3, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

8. (New) A method of treating a corneal disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound having an effect of activating Rho.

9. (New) The method as claimed in claim 8, wherein the compound having the effect of activating Rho is lysophosphatidic acid or an acyl derivative thereof, wherein said acyl is a saturated or unsaturated higher aliphatic carbonyl or aromatic carbonyl.

10. (New) The method as claimed in claim 9, wherein said compound having the effect of activating Rho is oleoyl lysophosphatidic acid.

11. (New) The method as claimed in claim 8, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

12. (New) The method as claimed in claim 9, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

13. (New) The method as claimed in claim 10, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

REMARKS

It is respectfully submitted that the amended claims and the new claims are supported by the original disclosure and